WO2011147910A1 - Pyrazole compounds as sigma receptor inhibitors - Google Patents
Pyrazole compounds as sigma receptor inhibitors Download PDFInfo
- Publication number
- WO2011147910A1 WO2011147910A1 PCT/EP2011/058633 EP2011058633W WO2011147910A1 WO 2011147910 A1 WO2011147910 A1 WO 2011147910A1 EP 2011058633 W EP2011058633 W EP 2011058633W WO 2011147910 A1 WO2011147910 A1 WO 2011147910A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pyrazol
- substituted
- unsubstituted
- methoxy
- methyl
- Prior art date
Links
- 0 CCC(C)(CC(C)(C)*Cc1n[n](*)c(*)c1*)N(*)* Chemical compound CCC(C)(CC(C)(C)*Cc1n[n](*)c(*)c1*)N(*)* 0.000 description 3
- XSRHUAUVDVPISH-UHFFFAOYSA-N CC[O](C)(C)C(c(cc1C)n[n]1-c(cc1)cc(Cl)c1Cl)=O Chemical compound CC[O](C)(C)C(c(cc1C)n[n]1-c(cc1)cc(Cl)c1Cl)=O XSRHUAUVDVPISH-UHFFFAOYSA-N 0.000 description 1
- DPJZKJVDCIMWCL-UHFFFAOYSA-N Clc(ccc(NNCl)c1)c1Cl Chemical compound Clc(ccc(NNCl)c1)c1Cl DPJZKJVDCIMWCL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Description
Claims
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012013667A MX338226B (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors. |
KR1020127034130A KR101819680B1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
UAA201214968A UA112160C2 (en) | 2010-05-27 | 2011-05-26 | Pirazol Compounds as Sigma Receptor Inhibitors |
BR112012030024-5A BR112012030024B1 (en) | 2010-05-27 | 2011-05-26 | compound, process for the preparation of the same and medicine comprising the same |
CA2800103A CA2800103C (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
MEP-2017-50A ME02625B (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
NZ603532A NZ603532A (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
RS20170229A RS55750B1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
SI201131115A SI2576543T1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
EP11723422.9A EP2576543B1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
SG2012086203A SG185720A1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
CN201180026049.9A CN103003267B (en) | 2010-05-27 | 2011-05-26 | Sigma receptor inhibitors |
US13/699,341 US9181195B2 (en) | 2010-05-27 | 2011-05-26 | Sigma receptor inhibitors |
RU2012156925/04A RU2582338C2 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
ES11723422.9T ES2616084T3 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
MA35483A MA34331B1 (en) | 2010-05-27 | 2011-05-26 | PYRAZOLE COMPOUNDS AS INHIBITORS OF THE SIGMA RECEPTOR |
AU2011257208A AU2011257208B2 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
DK11723422.9T DK2576543T3 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
LTEP11723422.9T LT2576543T (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
JP2013511681A JP5932779B2 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
TNP2012000534A TN2012000534A1 (en) | 2010-05-27 | 2012-11-09 | Pyrazole compounds as sigma receptor inhibitors |
ZA2012/08799A ZA201208799B (en) | 2010-05-27 | 2012-11-22 | Pyrazole compounds as sigma receptor inhibitors |
IL223300A IL223300A (en) | 2010-05-27 | 2012-11-27 | Pyrazole derivatives and their use for the treatment and/or prophylaxis of sigma receptor-mediated diseases or conditions |
CY20171100280T CY1118682T1 (en) | 2010-05-27 | 2017-03-02 | PYRAZOL UNIONS AS SUSPENSIONS OF THE RECEPTOR SIGMA |
HRP20170361TT HRP20170361T1 (en) | 2010-05-27 | 2017-03-06 | Pyrazole compounds as sigma receptor inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10382148A EP2395003A1 (en) | 2010-05-27 | 2010-05-27 | Pyrazole compounds as sigma receptor inhibitors |
EP10382148.4 | 2010-05-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011147910A1 true WO2011147910A1 (en) | 2011-12-01 |
Family
ID=42931975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2011/058633 WO2011147910A1 (en) | 2010-05-27 | 2011-05-26 | Pyrazole compounds as sigma receptor inhibitors |
Country Status (33)
Country | Link |
---|---|
US (1) | US9181195B2 (en) |
EP (2) | EP2395003A1 (en) |
JP (2) | JP5932779B2 (en) |
KR (1) | KR101819680B1 (en) |
CN (1) | CN103003267B (en) |
AR (1) | AR081426A1 (en) |
AU (1) | AU2011257208B2 (en) |
BR (1) | BR112012030024B1 (en) |
CA (1) | CA2800103C (en) |
CO (1) | CO6640327A2 (en) |
CY (1) | CY1118682T1 (en) |
DK (1) | DK2576543T3 (en) |
EC (1) | ECSP12012270A (en) |
ES (1) | ES2616084T3 (en) |
HR (1) | HRP20170361T1 (en) |
HU (1) | HUE031755T2 (en) |
IL (1) | IL223300A (en) |
LT (1) | LT2576543T (en) |
MA (1) | MA34331B1 (en) |
ME (1) | ME02625B (en) |
MX (1) | MX338226B (en) |
NZ (1) | NZ603532A (en) |
PL (1) | PL2576543T3 (en) |
PT (1) | PT2576543T (en) |
RS (1) | RS55750B1 (en) |
RU (1) | RU2582338C2 (en) |
SG (1) | SG185720A1 (en) |
SI (1) | SI2576543T1 (en) |
TN (1) | TN2012000534A1 (en) |
TW (1) | TWI507195B (en) |
UA (1) | UA112160C2 (en) |
WO (1) | WO2011147910A1 (en) |
ZA (1) | ZA201208799B (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015521994A (en) * | 2012-07-04 | 2015-08-03 | ラボラトリオス・デル・ドクトル・エステヴェ・エス・アLaboratorios Del Dr. Esteve, S.A. | Imidazo [2,1-b] thiazole derivatives, process for their production and use as pharmaceuticals |
WO2016096125A1 (en) * | 2014-12-15 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma receptor ligands in osteoarthritis |
WO2017037166A1 (en) * | 2015-09-02 | 2017-03-09 | Laboratorios Del Dr. Esteve, S.A. | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts |
US9757358B2 (en) | 2010-02-04 | 2017-09-12 | Laboratorios Del Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US9782483B2 (en) | 2010-05-21 | 2017-10-10 | Laboratories Del Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
US9789117B2 (en) | 2011-05-18 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
US9789115B2 (en) | 2010-08-03 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
US9844516B2 (en) | 2010-02-04 | 2017-12-19 | Laboratorios De Dr. Esteve | Sigma ligands for use in the prevention and/or treatment of post-operative pain |
US9914705B2 (en) | 2008-04-25 | 2018-03-13 | Laboratorios Del Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
US9931346B2 (en) | 2013-12-17 | 2018-04-03 | Laboratorios Del Dr. Esteve S.A. | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations |
EP3336085A1 (en) | 2016-12-15 | 2018-06-20 | Laboratorios del Dr. Esteve S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
KR20160098506A (en) * | 2013-12-20 | 2016-08-18 | 라보라토리오스 델 드라. 에스테브.에스.에이. | Piperazine derivatives having multimodal activity against pain |
CN103896835A (en) * | 2014-04-20 | 2014-07-02 | 武汉珈瑜科技有限公司 | Quinolinone derivatives and application thereof |
WO2016096127A1 (en) * | 2014-12-15 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Methyl-1h-pyrazole alkylamine compounds having multimodal activity against pain |
JP6761413B2 (en) | 2015-06-11 | 2020-09-23 | 富士フイルム富山化学株式会社 | Sigma receptor binder |
CN111793032B (en) * | 2019-04-08 | 2021-11-19 | 四川省中医药科学院 | Pyrazolone compounds and preparation method and application thereof |
CN113929649B (en) * | 2021-11-22 | 2022-11-01 | 河北化工医药职业技术学院 | Preparation method of coriolide derivative |
Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2301250A1 (en) | 1975-02-21 | 1976-09-17 | Bellon Labor Sa Roger | 3-Omega dialkyl amino alkoxy 1,4-diaryl 1H-pyrazoles - analgesics and antiinflammatories prepd. from 3-hydroxy pyrazoles and alkyl halides |
US4337263A (en) | 1979-07-05 | 1982-06-29 | Laboratoire Roger Bellon | 1-Aryl-4-γ-arylsulphonyl-3-aminopropoxy-1H-pyrazoles and their use as hypolipemiant and hypocholesterolemiant agents |
EP0248594A2 (en) * | 1986-05-29 | 1987-12-09 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same |
EP0414289A1 (en) | 1989-07-26 | 1991-02-27 | Merck Sharp & Dohme Ltd. | Spirocyclic antipsychotic agents |
EP0431943A2 (en) | 1989-12-08 | 1991-06-12 | Merck & Co. Inc. | Nitrogen-containing spirocycles |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
EP0445974A2 (en) | 1990-03-05 | 1991-09-11 | MERCK SHARP & DOHME LTD. | Spirocyclic antipsychotic agents |
EP0518805A1 (en) | 1991-06-13 | 1992-12-16 | H. Lundbeck A/S | Piperidine derivatives |
EP0529973A1 (en) | 1991-08-26 | 1993-03-03 | Rohm And Haas Company | Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles |
WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
WO2004016592A1 (en) | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
WO2004017961A2 (en) | 2002-08-21 | 2004-03-04 | Astrazeneca Ab | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer |
JP2004196678A (en) * | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | Pyrazole-based derivative |
WO2006021462A1 (en) | 2004-08-27 | 2006-03-02 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
EP1829866A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
WO2007098964A2 (en) | 2006-03-02 | 2007-09-07 | Laboratorios Del Dr. Esteve S.A. | Pyrrazole derivatives as sigma receptors antagonists |
WO2008108517A2 (en) * | 2007-03-08 | 2008-09-12 | Korea Research Institute Of Chemical Technology | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7829560B2 (en) * | 2004-07-08 | 2010-11-09 | Arqule, Inc. | 1,4-disubstituted naphthalenes as inhibitors of P38 MAP kinase |
DK1781618T3 (en) * | 2004-08-27 | 2012-10-29 | Esteve Labor Dr | Sigma receptor inhibitors |
CN101248049B (en) * | 2005-06-27 | 2013-08-28 | 埃克塞利希斯专利有限责任公司 | Imidazole based lxr modulators |
EP1829867A1 (en) * | 2006-03-03 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Imidazole compounds having pharmaceutical activity towards the sigma receptor |
WO2007108517A1 (en) | 2006-03-22 | 2007-09-27 | Matsushita Electric Industrial Co., Ltd. | Blood inspection device |
EP1921071A1 (en) | 2006-11-10 | 2008-05-14 | Laboratorios del Dr. Esteve S.A. | 1,2,3- triazole derivatives as sigma receptor inhibitors |
EP2113501A1 (en) | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
EP2395003A1 (en) * | 2010-05-27 | 2011-12-14 | Laboratorios Del. Dr. Esteve, S.A. | Pyrazole compounds as sigma receptor inhibitors |
-
2010
- 2010-05-27 EP EP10382148A patent/EP2395003A1/en not_active Withdrawn
-
2011
- 2011-05-26 AU AU2011257208A patent/AU2011257208B2/en not_active Ceased
- 2011-05-26 NZ NZ603532A patent/NZ603532A/en not_active IP Right Cessation
- 2011-05-26 HU HUE11723422A patent/HUE031755T2/en unknown
- 2011-05-26 UA UAA201214968A patent/UA112160C2/en unknown
- 2011-05-26 DK DK11723422.9T patent/DK2576543T3/en active
- 2011-05-26 SG SG2012086203A patent/SG185720A1/en unknown
- 2011-05-26 RU RU2012156925/04A patent/RU2582338C2/en active
- 2011-05-26 JP JP2013511681A patent/JP5932779B2/en active Active
- 2011-05-26 PT PT117234229T patent/PT2576543T/en unknown
- 2011-05-26 PL PL11723422T patent/PL2576543T3/en unknown
- 2011-05-26 MA MA35483A patent/MA34331B1/en unknown
- 2011-05-26 RS RS20170229A patent/RS55750B1/en unknown
- 2011-05-26 US US13/699,341 patent/US9181195B2/en active Active
- 2011-05-26 ES ES11723422.9T patent/ES2616084T3/en active Active
- 2011-05-26 CA CA2800103A patent/CA2800103C/en active Active
- 2011-05-26 SI SI201131115A patent/SI2576543T1/en unknown
- 2011-05-26 ME MEP-2017-50A patent/ME02625B/en unknown
- 2011-05-26 KR KR1020127034130A patent/KR101819680B1/en active IP Right Grant
- 2011-05-26 EP EP11723422.9A patent/EP2576543B1/en active Active
- 2011-05-26 CN CN201180026049.9A patent/CN103003267B/en active Active
- 2011-05-26 LT LTEP11723422.9T patent/LT2576543T/en unknown
- 2011-05-26 BR BR112012030024-5A patent/BR112012030024B1/en not_active IP Right Cessation
- 2011-05-26 MX MX2012013667A patent/MX338226B/en active IP Right Grant
- 2011-05-26 WO PCT/EP2011/058633 patent/WO2011147910A1/en active Application Filing
- 2011-05-27 AR ARP110101819A patent/AR081426A1/en unknown
- 2011-05-27 TW TW100118671A patent/TWI507195B/en active
-
2012
- 2012-10-17 EC ECSP12012270 patent/ECSP12012270A/en unknown
- 2012-11-09 TN TNP2012000534A patent/TN2012000534A1/en unknown
- 2012-11-22 ZA ZA2012/08799A patent/ZA201208799B/en unknown
- 2012-11-27 IL IL223300A patent/IL223300A/en active IP Right Grant
- 2012-12-27 CO CO12234896A patent/CO6640327A2/en unknown
-
2015
- 2015-11-26 JP JP2015230490A patent/JP2016065092A/en active Pending
-
2017
- 2017-03-02 CY CY20171100280T patent/CY1118682T1/en unknown
- 2017-03-06 HR HRP20170361TT patent/HRP20170361T1/en unknown
Patent Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2301250A1 (en) | 1975-02-21 | 1976-09-17 | Bellon Labor Sa Roger | 3-Omega dialkyl amino alkoxy 1,4-diaryl 1H-pyrazoles - analgesics and antiinflammatories prepd. from 3-hydroxy pyrazoles and alkyl halides |
US4337263A (en) | 1979-07-05 | 1982-06-29 | Laboratoire Roger Bellon | 1-Aryl-4-γ-arylsulphonyl-3-aminopropoxy-1H-pyrazoles and their use as hypolipemiant and hypocholesterolemiant agents |
EP0248594A2 (en) * | 1986-05-29 | 1987-12-09 | Ortho Pharmaceutical Corporation | Pharmacologically active 1,5-diaryl-3-substituted-pyrazoles and method for synthesizing the same |
EP0414289A1 (en) | 1989-07-26 | 1991-02-27 | Merck Sharp & Dohme Ltd. | Spirocyclic antipsychotic agents |
EP0431943A2 (en) | 1989-12-08 | 1991-06-12 | Merck & Co. Inc. | Nitrogen-containing spirocycles |
WO1991009594A1 (en) | 1989-12-28 | 1991-07-11 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
EP0445974A2 (en) | 1990-03-05 | 1991-09-11 | MERCK SHARP & DOHME LTD. | Spirocyclic antipsychotic agents |
EP0518805A1 (en) | 1991-06-13 | 1992-12-16 | H. Lundbeck A/S | Piperidine derivatives |
EP0529973A1 (en) | 1991-08-26 | 1993-03-03 | Rohm And Haas Company | Fungicidal 2-aryl-2-cyano-2-(heterocyclylalkyl)ethyl-1,2,4-triazoles |
US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
US20030144309A1 (en) | 2001-05-16 | 2003-07-31 | Young Choon-Moon | Inhibitors of Src and other protein kinases |
WO2002102387A1 (en) | 2001-06-18 | 2002-12-27 | H. Lundbeck A/S | Treatment of neuropathic pain |
US6509367B1 (en) * | 2001-09-22 | 2003-01-21 | Virginia Commonwealth University | Pyrazole cannabinoid agonist and antagonists |
WO2004016592A1 (en) | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
WO2004017961A2 (en) | 2002-08-21 | 2004-03-04 | Astrazeneca Ab | Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer |
JP2004196678A (en) * | 2002-12-17 | 2004-07-15 | Dainippon Pharmaceut Co Ltd | Pyrazole-based derivative |
WO2006021462A1 (en) | 2004-08-27 | 2006-03-02 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
WO2007002559A1 (en) * | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Pyrazole based lxr modulators |
WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
EP1829866A1 (en) * | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
WO2007098964A2 (en) | 2006-03-02 | 2007-09-07 | Laboratorios Del Dr. Esteve S.A. | Pyrrazole derivatives as sigma receptors antagonists |
WO2008108517A2 (en) * | 2007-03-08 | 2008-09-12 | Korea Research Institute Of Chemical Technology | Piperazinyl-propyl-pyrazole derivatives as dopamine d4 receptor antagonists, and pharmaceutical compositions containing the same |
Non-Patent Citations (30)
Title |
---|
"Design and Applications of Prodrugs", 1985, HARWOOD ACADEMIC PUBLISHERS |
"Stedman's Medical Spellchecker", 2006, LIPPINCOTT WILLIAMS & WILKINS |
ANGEW. CHEM., INT. ED., vol. 37, 1998, pages 2090 |
BURGER: ""Medicinal Chemistry and Drug Discovery", 2001, WILEY |
CHEM. REV., vol. 89, 1989, pages 863 - 927 |
D.-M. SHEN, M. SHU, K. T. CHAPMAN: "Versatile and Efficient Solid-Phase Syntheses of Pyrazoles and Isoxazoles", ORGANIC LETTERS, vol. 2, no. 18, 8 April 2000 (2000-04-08), pages 2789 - 2792, XP002605610 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Diethyl-[3-(5-methyl-1-phenyl-1H-pyrazol-3-yl)-propyl]amine", XP002605612, Database accession no. 213356 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{3-[5-(4-nitro-phenyl)-1-phenyl-1H-pyrazol-3-yl]propyl}-amine", XP002605613, Database accession no. 705147 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{4-[5-(4-nitro-phenyl)-1-phenyl-1H-pyrazol-3-yl]-butyl}amine", XP002605614, Database accession no. 706821 * |
DATABASE BEILSTEIN [online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; "Methyl-{5-[5-(4-nitro-phenyl)-1-phenyl-1H-pyrazol-3-yl]-pentyl}-amine", XP002605615, Database accession no. 710983 * |
DATABASE WPI Week 200451, Derwent World Patents Index; AN 2004-529624, XP002605609 * |
DEHAVEN-HUDKINS, D. L., L.C. FLEISSNER, F. Y. FORD-RICE: "Characterization of the binding of [3H](+)pentazocine to ? recognition sites in guinea pig brain", EUR. J. PHARMACOL., vol. 227, 1992, pages 371 - 378, XP023861851, DOI: doi:10.1016/0922-4106(92)90153-M |
GABRIEL TOJO, MARCOS FERNANDEZ: "Oxidation of Alcoholes to Aldehydes and Ketones: A Guide to Current Common Practice", 2006, SPRINGER |
HANNER, M. ET AL., PROC. NATL. ACAD. SCI., vol. 93, 1996, pages 8072 - 8077 |
I. GOSNEY, A. G. ROWLEY: "Organophosphorous Reagents in Organic Synthesis", 1979, ACADEMIC PRESS |
J ORG. CHEM., vol. 49, 1984, pages 4293 - 4295 |
J. AM. CHEM. SOC., vol. 120, 1998, pages 6621 |
K. V. SHVIDENKO, K. G. NAZARENKO, T. I. SHVIDENKO, A. A. TOLMACHEV: "Recyclization Reactions of 2-(1-Benzoylpyrrolidin-2-ylidene)malononitrile", CHEMISTRY OF HETEROCYCLIC COMPOUNDS, vol. 46, no. 1, 1 May 2010 (2010-05-01), pages 56 - 60, XP002605611 * |
KROGSGAARD-LARSEN ET AL.: "Textbook of Drug design and Discovery", April 2002, TAYLOR & FRANCIS |
LOWRY, O.H., N.J. ROSEBROUGH, A.L. FARR, R.J. RANDALL: "Protein measurement with the Folin phenol reagent", J. BIOL. CHEM, vol. 193, 1951, pages 265, XP000196391 |
M. J. S. DEWAR: "Attempts to find new Antimalarials. Part XXI", JOURNAL OF THE CHEMICAL SOCIETY, 1944, pages 615 - 619 * |
PAUL N. RYLANDER: "Hydrogenation Methods", 1990, ACADEMIC PRESS |
PETRIE C R ET AL: "A NOVEL BIOTINYLATED ADENYLATE ANALOGUE DERIVED FROM PYRAZOLOÚ3,4-D 3/4 PYRIMIDINE FOR LABELING DNA PROBES", BIOCONJUGATE CHEMISTRY, ACS, WASHINGTON, DC, US LNKD- DOI:10.1021/BC00012A011, vol. 2, no. 6, 1 November 1991 (1991-11-01), pages 441 - 446, XP000572789, ISSN: 1043-1802 * |
QUIRION, R. ET AL., TRENDS PHARMACOL. SCI., vol. 13, 1992, pages 85 - 86 |
SNYDER, S.H., LARGENT, B.L., J. NEUROPSYCHIATRY, vol. 1, 1989, pages 7 |
TETRAHEDRON LETTERS, vol. 51, 2010, pages 2741 |
TOP. STEREOCHEM., vol. 21, no. 1, 1994 |
TOP., STEREOCHEM., vol. 21, 1994, pages 1 |
V. VIRMANI ET AL., INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY, vol. 17, 1979, pages 472 - 477 * |
WALKER, J.M. ET AL., PHARMACOLOGICAL REVIEWS, vol. 42, 1990, pages 355 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9914705B2 (en) | 2008-04-25 | 2018-03-13 | Laboratorios Del Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy pyrazoles as sigma ligands enhancing analgesic effect of opioids and attenuating the dependency thereof |
US9757358B2 (en) | 2010-02-04 | 2017-09-12 | Laboratorios Del Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
US9844516B2 (en) | 2010-02-04 | 2017-12-19 | Laboratorios De Dr. Esteve | Sigma ligands for use in the prevention and/or treatment of post-operative pain |
US9782483B2 (en) | 2010-05-21 | 2017-10-10 | Laboratories Del Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
US9789115B2 (en) | 2010-08-03 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
US9789117B2 (en) | 2011-05-18 | 2017-10-17 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
JP2015521994A (en) * | 2012-07-04 | 2015-08-03 | ラボラトリオス・デル・ドクトル・エステヴェ・エス・アLaboratorios Del Dr. Esteve, S.A. | Imidazo [2,1-b] thiazole derivatives, process for their production and use as pharmaceuticals |
US9931346B2 (en) | 2013-12-17 | 2018-04-03 | Laboratorios Del Dr. Esteve S.A. | Serotonin-norepinephrine reuptake inhibitors (SNRIs) and Sigma receptor ligands combinations |
WO2016096125A1 (en) * | 2014-12-15 | 2016-06-23 | Laboratorios Del Dr. Esteve, S.A. | Use of sigma receptor ligands in osteoarthritis |
WO2017037166A1 (en) * | 2015-09-02 | 2017-03-09 | Laboratorios Del Dr. Esteve, S.A. | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl) piperazin-1-yl)ethanone salts |
US20180251430A1 (en) * | 2015-09-02 | 2018-09-06 | Laboratorios Del Dr. Esteve, S.A. | 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone salts |
US10640468B2 (en) | 2015-09-02 | 2020-05-05 | Esteve Pharmaceuticals, S.A. | 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-Yl)methoxy)ethyl)piperazin-1- Yl)ethanone salts |
RU2727974C2 (en) * | 2015-09-02 | 2020-07-28 | Лабораторьос Дель Др. Эстеве, С.А. | Salts of 1-(4-(2-((1-(3,4-difluorophenyl)-1n-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
AU2016315396B2 (en) * | 2015-09-02 | 2021-05-27 | Laboratorios Del Dr. Esteve, S.A. | 1-(4-(2-((1-(3,4-difluorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone salts |
EP3336085A1 (en) | 2016-12-15 | 2018-06-20 | Laboratorios del Dr. Esteve S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
WO2018109082A1 (en) | 2016-12-15 | 2018-06-21 | Laboratorios Del Dr. Esteve, S.A. | Process and intermediate for the preparation of 1-(4-(2-((1-(3,4- difluorophenyl)-1h-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2576543T3 (en) | Pyrazole compounds as sigma receptor inhibitors | |
EP1781618B1 (en) | Sigma receptor inhibitors | |
US8202872B2 (en) | Pyrazole derivatives as sigma receptor inhibitors | |
US8314096B2 (en) | Sigma receptor inhibitors | |
EP1996554B1 (en) | Sigma receptor inhibitors | |
EP1994008B1 (en) | Imidazole compounds having pharmaceutical activity towards the sigma receptor | |
EP1829875A1 (en) | Pyrazole derivatives as sigma receptor inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11723422 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2800103 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12012502295 Country of ref document: PH |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/013667 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2013511681 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 223300 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2011257208 Country of ref document: AU Date of ref document: 20110526 Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2011723422 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011723422 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10661/CHENP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201214968 Country of ref document: UA |
|
ENP | Entry into the national phase |
Ref document number: 2012156925 Country of ref document: RU Kind code of ref document: A Ref document number: 20127034130 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12234896 Country of ref document: CO |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13699341 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012030024 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012030024 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121126 |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0229 Country of ref document: RS |